Sarepta Therapeutics,, Inc. Common Stock
Veridion Score
Composite trend over time
Why is SRPT moving today?
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for SRPT.
SRPT insider activity
Sarepta Therapeutics,, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Net selling: -$693K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-03-13 | 2026-03-12 | Mayo Stephen | Insider | sell | $17.02 | 7,239 | 1,765 | $123K | SEC Form 4 |
| 2026-03-13 | 2026-03-11 | Wong Ryan Ho-Yan | Insider | sell | $17.03 | 256 | 135,064 | $4K | SEC Form 4 |
| 2026-03-13 | 2026-03-11 | Rothfuss Cristin | Insider | sell | $17.03 | 974 | 137,544 | $17K | SEC Form 4 |
| 2026-03-13 | 2026-03-11 | Estepan Ian Michael | Insider | sell | $17.03 | 1,097 | 201,983 | $19K | SEC Form 4 |
| 2026-03-13 | 2026-03-11 | Rodino-Klapac Louise | Insider | sell | $17.03 | 948 | 225,323 | $16K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 26 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moSRPT contract awards, year to date.
Public federal awards linked to this ticker.
SRPT lobbying filings, year to date.
Registered lobbying filings matched to Sarepta Therapeutics,, Inc. Common Stock.